JP Morgan Chase
TCRX icon

JP Morgan Chase’s TScan Therapeutics TCRX Stock Holding History

JP Morgan Chase’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Buy
16,458
+22
+0.1% +$23 ﹤0.01% 6785
2026
Q1 		$15.5K Sell
16,436
-16,913
-51% -$18.1K ﹤0.01% 6627
2025
Q4 		$33.3K Sell
33,349
-204,401
-86% -$296K ﹤0.01% 6375
2025
Q3 		$433K Sell
237,750
-49,993
-17% -$88.6K ﹤0.01% 5118
2025
Q2 		$417K Buy
287,743
+22,642
+9% +$32.7K ﹤0.01% 4871
2025
Q1 		$366K Buy
265,101
+198,345
+297% +$429K ﹤0.01% 4959
2024
Q4 		$203K Buy
66,756
+34,951
+110% +$158K ﹤0.01% 5467
2024
Q3 		$158K Buy
31,805
+15,441
+94% +$93.2K ﹤0.01% 5511
2024
Q2 		$95.7K Sell
16,364
-50,649
-76% -$399K ﹤0.01% 5537
2024
Q1 		$532K Buy
67,013
+33,783
+102% +$213K ﹤0.01% 4750
2023
Q4 		$194K Buy
+33,230
New +$152K ﹤0.01% 5404
2022
Q2 		– Sell
-361
Closed -$1K – 6882
2022
Q1 		$1K Buy
+361
New +$1.56K ﹤0.01% 6501

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

JP Morgan Chase's TCRX Position: Q2 2026 in Review

JP Morgan Chase increased its TScan Therapeutics (TCRX) stake by 0.13% in Q2 2026, buying an estimated $23 and bringing the position to 16,458 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6785.

JP Morgan Chase first reported a position in TCRX in Q1 2022 and has held it in 12 quarters since. The position peaked at $532K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • JP Morgan Chase held 16,458 shares of TScan Therapeutics worth $16.1K as of Q2 2026.
  • JP Morgan Chase bought 22 TScan Therapeutics shares in Q2 2026, an estimated $23.
  • TScan Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6785 holding.
  • JP Morgan Chase first reported a position in TScan Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • JP Morgan Chase's TScan Therapeutics position peaked at $532K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.